Free Biopharma Daily Stock Updates - 04/12/22
$XBI $87.15 | -.019% Covid Updates $ Pipeline Updates $TPTX +0.6% Turning Point Therapeutics Announces Positive Topline Data by Blinded...
top of page
BPIQ Blog
Apr 11, 20222 min read
Free Biopharma Daily Stock Updates - 04/11/22
$XBI $87.32 | -3.34% Covid Updates $ Pipeline Updates $AGLE -6.5% Aeglea BioTherapeutics Presents Additional Data from PEACE Phase 3...
Apr 8, 20222 min read
Biopharma Pulse - 4/4 - 4/8 Week in Review
As we have reached the end of the first full week of April, we review moves from smid-cap biopharma companies during this past week as...
Apr 8, 20222 min read
Free Biopharma Daily Stock Updates - 04/08/22
$XBI $90.34 | +-2.3% Covid Updates $NVAX +1.9% Novavax and Serum Institute of India Receive Emergency Use Authorization for Novavax'...
Apr 7, 20221 min read
Free Biopharma Daily Stock Updates - 04/07/22
$XBI $92.43 | -0.96% Covid Updates $ Pipeline Updates $MNOV +3.9% MediciNova Announces Secondary Analysis of Phase 2 Trial of MN-166...
Apr 7, 20222 min read
American Association for Cancer Research (AACR) Annual Meeting 2022
Summary The American Association for Cancer Research (AACR) annual meeting takes place from April 8-13, 2022 online and in New Orleans...
Apr 7, 20223 min read
CHRS - Bull Thesis
CHRS is a very unusual small-cap biopharma stock because it started as. and still remains in part, a biosimilar company. A biosimilar is...
Apr 6, 20222 min read
Free Biopharma Daily Stock Updates - 04/06/22
$XBI $93.33 | +0.086% Covid Updates $ Pipeline Updates $SPRO -4.1% Spero Therapeutics Tebipenem Pivoxil Hydrobromide Phase 3 Data...
Apr 6, 20222 min read
GBT - Bull Thesis
BULL THESIS GBT overall corporate and executive summary Cash of $735M in Q4 ‘21, almost doubled in last quarter A little over 2 years of...
Apr 5, 20221 min read
Free Biopharma Daily Stock Updates - 04/05/22
$XBI $93.25 | -2.96% Covid Updates $TNXP -4.9% Tonix Pharmaceuticals Announces Extension of Sponsored Research Agreement with Kansas...
Apr 4, 20223 min read
Free Biopharma Daily Stock Updates - 04/04/22
$XBI $96.09 | +3.0% Covid Updates $ALGS +4.0% Aligos Therapeutics Selects Drug Candidate ALG-097558, a Potent Ritonavir-Free Oral...
Apr 2, 20222 min read
Free Biopharma Daily Stock Updates - 04/01/22
$XBI $93.26 | +3.76% Pipeline Updates $CYTK Cytokinetics Announces Results From Cohort 3 of Redwood-HCM Presented at American College of...
Apr 1, 20222 min read
Biopharma Pulse - 3/28 - 4/1 Week in Review
As March concluded this week, we review moves from smid-cap biopharma companies during this past week as well as March as a whole. See...
Mar 31, 20222 min read
Free Biopharma Daily Stock Updates - 03/31/22
$XBI $89.88 | -0.88% Covid Updates $SRNE -1.7% Sorrento Reports FDA Clearance for the Commencement of a Phase 2/3 Study for Abivertinib...
Mar 30, 20221 min read
Free Biopharma Daily Stock Updates - 03/30/22
$XBI $90.68 | -3.07% Covid Updates $CYDY +0.8% CytoDyn Announces Partial Clinical Hold of HIV Program and Full Clinical Hold of COVID-19...
Mar 29, 20222 min read
Free Biopharma Daily Stock Updates - 03/29/22
$XBI $93.55 | +4.28% Covid Updates $BNTX +3.6% & $PFE -1.0% Pfizer and BioNTech Receive Expanded U.S. Emergency Use Authorization for...
Mar 28, 20222 min read
Free Biopharma Daily Stock Updates - 03/28/22
$XBI $89.71 | +0.1% Covid Updates $ Pipeline Updates $NBIX -0.1% Neurocrine Biosciences Announces Regulatory Approval of Dysval®...
Mar 26, 20222 min read
Free Biopharma Daily Stock Updates - 03/25/22
$XBI $89.62 | -2.34% Covid Updates $VIR US Food and Drug Administration Revises Emergency Use Authorization for Sotrovimab Due to...
Mar 25, 20221 min read
Biopharma Pulse - 3/21 - 3/25 Week in Review
As we near the end of March, we review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and...
Mar 24, 20221 min read
Free Biopharma Daily Stock Updates - 03/24/22
$XBI $91.77 | +2.13% Covid Updates $AZN +2.6% Evusheld long-acting antibody combination recommended for approval in the EU for the...
Jump start your biotech due diligence
Our platform helps you uncover your next biotech investment opportunity
bottom of page